Business & Finance AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
By
· August 3, 2026 · 1 min read
This article was originally published by
Financial Times
and is republished here under license.
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Related
Versant noted revenue growth in its platforms business, which includes Fandango and GolfNow, and now, the recent acquisition of Full…
By
· August 6, 2026 · 1 min read
It will take time to restore credibility with investors after a disappointing first earnings report.…
By
· August 6, 2026 · 1 min read
Anthropic, Meta and OpenAI have all had incidents of AI models hacking other companies during cybersecurity testing.…
By
· August 6, 2026 · 1 min read
Leave a Reply